Lubiprostone
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-R-0022
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Defense Logistics Agency (DLA Troop Support) has issued a solicitation for a national requirements contract to supply Lubiprostone Capsules, specifically in 24MCG and 8MCG strengths, packaged in 60-count bottles. This procurement is intended to establish a reliable, nationwide supply source for these pharmaceutical products, supporting the needs of the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will facilitate purchases through the DLA and VA prime vendor programs, ensuring consistent availability for federal healthcare providers.
The scope of this solicitation encompasses the provision of Lubiprostone Capsules as commercial items, with annual usage estimates detailed in the Schedule of Supplies section of the solicitation. The acquisition will be conducted as an unrestricted and fully competitive process, inviting proposals from all qualified sources. The resulting contract will be a firm-fixed price, requirements type agreement, featuring a one-year base period and four one-year option periods, thereby offering potential contractors a multi-year business opportunity.
Key requirements include the ability to manufacture and supply Lubiprostone Capsules in both specified dosages and packaging formats, in accordance with the standards set forth in the solicitation. Contractors must be capable of meeting the projected national demand and ensuring timely delivery to designated federal customers. The procurement will be governed by Federal Acquisition Regulation (FAR) Part 12 for commercial items, and FAR 52.216-21 (Requirements), emphasizing the need for compliance with federal contracting standards.
The solicitation is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals), indicating the requirement for expertise in pharmaceutical manufacturing and distribution. There are no set-aside restrictions, making this opportunity accessible to all qualified vendors.
Interested parties can access the solicitation documents via the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and on SAM.gov at https://sam.gov. The solicitation is scheduled for release in October 2025, with proposals due by November 17, 2025. Contractors are encouraged to set up automated notifications for updates and changes to the solicitation.
For further information or inquiries, the primary point of contact is Jeremy Brown ([email protected], 445-737-5419), with secondary support available from Jason Wray ([email protected], 215-737-6304). The notice remains active and is posted on SAM.gov under Opportunity ID 8f8d2e745dbb454b962b70811f45997f.
This procurement represents a significant opportunity for pharmaceutical manufacturers with the capacity to supply Lubiprostone Capsules at a national scale, under a stable, multi-year federal contract. Contractors should review the solicitation in detail to ensure alignment with their capabilities and compliance with all federal requirements.